- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04185519
A Model of Computer-assisted Prescription of Erythropoiesis-stimulating Agents (ESA) in Patients Under Hemodialysis
Study Overview
Detailed Description
It has been known well for a long time that End stage renal disease (ESRD) patients usually need ESA to maintain their hemoglobin (Hb) to improve both mortality as well as quality of life. Later, several large-scale RCTs showing normalization of Hb in this population increased the risk of thromboembolic event, which leaded current guidelines to recommend the therapeutic goal for anemia in ESRD should be within a range (usually between 10-12 gm/dl) rather than above or below a certain level (or value). In addition to ESA dose, many factors contribute to the severity of anemia in this population, such as iron status, chronic blood loss, adequacy of dialysis, chronic inflammation, renal wasting, et al. To put all these factors together, maintaining the Hb levels within the target level is a challenge to physician. It was reported that only one third of Hb within the target at any given time. Our data showed, for those under maintenance hemodialysis and without any blood transfusion in observation period, near two third of patients' Hb level were within the target range.
For better anemia management, NKF-K/DOQI developed and published guidelines using protocol or algorithm for EPO prescription.6 Recently, artificial intelligence (AI) has been widely applied to medicine in the field of reducing human error, robotic surgical system and decision- making aid. Since then, there were several studies working on decision making programs to set up model of predicting the ESA dose needed for target Hb level. Artificial neural network (ANN) model is most commonly used for ESA dose-response prediction. However, the effectiveness of these kinds of AI is not confirmed clinically and the result not satisfactory. In other words, it is still inconclusive whether contemporary AI has any role in decision making aid when prescribing ESA dose for dialysis patient, a typical trial and error which AI supposed should be very helpful with.
Based on the mentioned above, we are going to conduct this clinical try to test the hypothesis that AI is not inferior to physician in prescribing ESA dose for hemodialysis patients to maintain hemoglobin(Hb) level to meet the target
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
TW
-
Kaohsiung, TW, Taiwan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
1. Main inclusion criteria:
- signed informed consent
- Age older than 20 year old.
- End stage renal disease under regular hemodialysis with three times per week and duration of each session at least 4 hours
- Having at least consecutive 6 months data of both Hb and biochemical study during dialysis before enrollment and at least one Hb level within the range of 11-12 g/dl
- Having at least one prescription of ESA supplement to keep Hb within the range of 10-12 g/dl in the past 6 months before the enrollment
- Having received ESA of the same brand at least 6 months before the enrollment
2. Main exclusion criteria:
- Ever receiving blood transfusion in the past 12 months
- Active bleeding with blood loss more than250cc in 3 months before the enrollment
- Active infection or malignancy
- Study subject can not follow with the study protocol 3. End of Study
The eligible subject will not be allowed to continue the study once informed consent is withdrawn or event happening meets the following criteria:
- Taking extra ESAs, Androgens and iron-chelating agents
- Undergoing surgery with massive haemorrhage, or blood transfusion
- Receiving systemic chemotherapy or radiotherapy or immunosuppressive therapies.
- The end of study will be 6 months later after the randomization of last study subject or failed prescription rate higher than 5%, which comes earlier.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AI (model)
This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl.
A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
|
The process of the experiment (brief describe) This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl.
A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl.
Once the failed rate by AI is higher than the physician is 5%, , the study will be terminated.
There will be three periods, namely ry 3 months.
|
No Intervention: DR1
Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hemoglobin (Hb) levels
Time Frame: 6 monthes
|
Primary analysis will be conducted after database lock and unblinded.
For hemoglobin (Hb) levels, the logistic regression model will include treatment (AI vs. conventional), center, and treatment-by-center interaction as factors, and mean change of the hemoglobin (Hb) levels from 11g/dl during the evaluation period as dependent variables, model-based point estimates and 95% confidence interval (CI) for the treatment effects will be calculated to test the primary outcome
|
6 monthes
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KMUHIRB-F(I)-20190094
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on AI (model)
-
Ensemble Group Holdings, LLCUnknown
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedAcute Respiratory FailureUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingProstatic Neoplasms | Lymphatic MetastasisChina
-
University of AlbertaRecruitingHealthy Volunteers | Pulmonary Hypertension | Interstitial Lung Disease | COPDCanada
-
West German Center of Diabetes and HealthRecruiting
-
Huazhong University of Science and TechnologyLanZhou University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University...CompletedPancreatic Ductal Adenocarcinoma | Pancreatitis, Chronic | Pancreatic Neuroendocrine Tumor | Autoimmune PancreatitisChina
-
Wuhan Asia Heart HospitalUnknownAnticoagulant-induced Bleeding | Warfarin Sodium Causing Adverse Effects in Therapeutic UseChina
-
Asian Institute of Gastroenterology, IndiaNot yet recruitingColonic Polyp | Artificial Intelligence
-
Mayo ClinicEnrolling by invitationArtificial Intelligence | Machine Learning | Limited English Proficiency | Language Barrier | Complex Medical NeedsUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting